Acceptability of bisphosphonates among patients, clinicians and managers: a systematic review and framework synthesis.
bone diseases
musculoskeletal disorders
rheumatology
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
03 11 2020
03 11 2020
Historique:
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
15
5
2021
Statut:
epublish
Résumé
To explore the acceptability of different bisphosphonate regimens for the treatment of osteoporosis among patients, clinicians and managers, payers and academics. A systematic review of primary qualitative studies. Seven databases were searched from inception to July 2019. Screening, data extraction and quality assessment of full-articles selected for inclusion were performed independently by two authors. A framework synthesis was applied to extracted data based on the theoretical framework of acceptability (TFA). The TFA includes seven domains relating to sense-making, emotions, opportunity costs, burden, perceived effectiveness, ethicality and self-efficacy. Confidence in synthesis findings was assessed. Any developed country healthcare setting. Patients, healthcare professionals, managers, payers and academics. Experiences and views of oral and intravenous bisphosphonates. Twenty-five studies were included, mostly describing perceptions of oral bisphosphonates. We identified, with high confidence, how patients and healthcare professionals make sense (coherence) of bisphosphonates by balancing perceptions of need against concerns, how uncertainty prevails about bisphosphonate perceived effectiveness and a number of individual and service factors that have potential to increase self-efficacy in recommending and adhering to bisphosphonates. We identified, with moderate confidence, that bisphosphonate taking induces concern, but has the potential to engender reassurance, and that both side effects and special instructions for taking oral bisphosphonates can result in treatment burden. Finally, we identified with low confidence that multimorbidity plays a role in people's perception of bisphosphonate acceptability. By using the lens of acceptability, our findings demonstrate with high confidence that a theoretically informed, whole-system approach is necessary to both understand and improve adherence. Clinicians and patients need supporting to understand the need for bisphosphonates, and clinicians need to clarify to patients what constitutes bisphosphonate treatment success. Further research is needed to explore perspectives of male patients and those with multimorbidity receiving bisphosphonates, and patients receiving intravenous treatment. CRD42019143526.
Identifiants
pubmed: 33148763
pii: bmjopen-2020-040634
doi: 10.1136/bmjopen-2020-040634
pmc: PMC7640526
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e040634Subventions
Organisme : Department of Health
ID : CS-2018-18-ST2-010
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Asthma. 2016 Dec;53(10):1051-8
pubmed: 27187172
Osteoporos Int. 2019 Jan;30(1):177-185
pubmed: 30306220
Patient Prefer Adherence. 2016 Nov 01;10:2217-2228
pubmed: 27843301
Calcif Tissue Int. 2019 Dec;105(6):589-608
pubmed: 31506706
Osteoporos Int. 2019 Nov;30(11):2155-2165
pubmed: 31388696
Arch Osteoporos. 2012;7:115-24
pubmed: 23225289
PLoS One. 2019 Jul 16;14(7):e0219681
pubmed: 31310619
BMC Med Res Methodol. 2011 Mar 16;11:29
pubmed: 21410933
Obstet Gynecol. 2013 Jun;121(6):1291-9
pubmed: 23812464
Curr Rheumatol Rep. 2015 Sep;17(9):61
pubmed: 26286178
J Health Serv Res Policy. 2007 Apr;12(2):95-100
pubmed: 17407659
BMJ Open. 2019 Mar 3;9(3):e024376
pubmed: 30833319
Am J Manag Care. 2009 Jun 01;15(6):e22-33
pubmed: 19514806
PLoS One. 2011 Apr 13;6(4):e18468
pubmed: 21533288
Qual Health Res. 2016 Aug;26(10):1307-17
pubmed: 27117960
Drugs Aging. 2010 Dec 1;27(12):999-1008
pubmed: 21087069
BMJ. 2009 Aug 11;339:b2803
pubmed: 19671932
Can Fam Physician. 2008 Mar;54(3):394-402
pubmed: 18337534
Arch Osteoporos. 2012;7:107-14
pubmed: 23225288
Can Fam Physician. 2003 Apr;49:462-8
pubmed: 12729242
Osteoporos Int. 1992 Nov;2(6):285-9
pubmed: 1421796
Arthritis Rheum. 2007 Feb 15;57(1):140-6
pubmed: 17266078
Osteoporos Int. 2008 Nov;19(11):1527-40
pubmed: 18373049
PLoS One. 2013 Dec 02;8(12):e80633
pubmed: 24312488
BMC Fam Pract. 2018 Aug 23;19(1):141
pubmed: 30139341
Rheumatol Int. 2015 Jan;35(1):97-103
pubmed: 24962740
Acta Orthop Traumatol Turc. 2016 Aug;50(4):415-23
pubmed: 27524671
J Eval Clin Pract. 2010 Jun;16(3):590-6
pubmed: 20102434
Osteoporos Int. 2016 May;27(5):1719-27
pubmed: 26759249
J Bone Miner Res. 2015 Dec;30(12):2179-87
pubmed: 26018247
Arch Osteoporos. 2015;10:231
pubmed: 26297076
Arch Osteoporos. 2017 Dec;12(1):22
pubmed: 28243883
J Bone Miner Res. 2016 Aug;31(8):1485-7
pubmed: 27335158
Osteoporos Int. 2006;17(9):1309-17
pubmed: 16804739
BMJ Open. 2017 Sep 29;7(9):e016047
pubmed: 28965092
Int J Clin Pract. 2016 Mar;70(3):261-76
pubmed: 26918508
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
PLoS One. 2014 Jan 02;9(1):e83552
pubmed: 24392086
Implement Sci. 2018 Jan 25;13(Suppl 1):2
pubmed: 29384079
BMC Womens Health. 2017 Mar 9;17(1):17
pubmed: 28279157
Qual Health Res. 2011 Dec;21(12):1692-704
pubmed: 21810994
J Geriatr Phys Ther. 2011 Apr-Jun;34(2):72-81
pubmed: 21937896
Osteoporos Int. 2017 Jan;28(1):219-229
pubmed: 27423660
BMC Musculoskelet Disord. 2011 May 09;12:92
pubmed: 21554729
BMC Health Serv Res. 2017 Mar 7;17(1):179
pubmed: 28270205
Osteoporos Int. 2008 Jul;19(7):1029-37
pubmed: 18193329
PLoS One. 2016 Jun 29;11(6):e0158365
pubmed: 27355576